Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab
Leuk Lymphoma
.
2019 Dec;60(13):3324-3326.
doi: 10.1080/10428194.2018.1519813.
Epub 2018 Oct 15.
Authors
Mireia Franch-Sarto
1
,
Marc Sorigue
1
,
Laia López
2
,
Miriam Moreno
1
,
Josep-Maria Ribera
1
,
Juan-Manuel Sancho
1
Affiliations
1
Department of Hematology, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
2
Department of Hematology, ICO-Hospital de Mataró, Mataró, Spain.
PMID:
30322316
DOI:
10.1080/10428194.2018.1519813
No abstract available
Publication types
Letter
Comment
MeSH terms
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Lymphoma, B-Cell*
Neoplasm Recurrence, Local
Oxaliplatin*
Retrospective Studies
Rituximab
Substances
Oxaliplatin
Deoxycytidine
Rituximab
Gemcitabine